HLB파나진

046210KOSDAQ의료용품 및 기타 의약 관련제품 제조업

47.5 / 100

Reference Date: 2026-06-10

Financial Score22.0 / 40

News Sentiment12.5 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Plunged 32.0% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

HLB Panajin is a specialized biotech venture company focusing on PNA (Peptide Nucleic Acid)-based bio materials and molecular diagnostics. The company develops and commercializes diverse diagnostic products, including somatic mutation detection, liquid biopsy, and automated diagnostic technologies, leveraging its PNA platform. Its subsidiary, BioSquare, expands into immunoassay technologies, while the company aims to build an AI-based diagnostic platform and develop PNA-based therapeutics for comprehensive healthcare solutions.

Number of Employees

84people

Average Salary

51.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 19.194.0Point

PBR

0.87Industry Average 1.305.5Point

Lower than industry avg (good)

ROE

-4.21Industry Average -4.893.5Point

Below industry avg

Debt Ratio

2.48Industry Average 6.866.5Point

Half of industry avg (excellent)

Trend 2023~20252.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲10.9% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼63.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -5.8% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 1,381Won52-week high 2,65052-week low 1,381

1-month return0.0Point

1m -31.97% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-06-09
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-09
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-08
Neutral분기보고서 (2026.03)2026-05-15